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Abstract  28 
The influence of vitamin D3 and its metabolites calcifediol (25(OH)D) and calcitriol on 29 
immune regulation and inflammation is well described, and raises the question of potential 30 
benefit against bacterial infections. In the current study, 25(OH)D was encapsulated in 31 
liposomes to enable aerosolisation, and tested for the ability to prevent pulmonary infection 32 
by Pseudomonas aeruginosa. Prepared 25(OH)D-loaded liposomes were nanosized and 33 
monodisperse, with a negative surface charge and a 25(OH)D entrapment efficiency of 34 
approximately 23%. Jet nebulisation of liposomes was seen to yield an aerosol suitable for 35 
tracheo-bronchial deposition. Interestingly, 25(OH)D in either liposomes or ethanolic solution 36 
had no effect on the release of the proinflammatory cytokine KC from Pseudomonas-infected 37 
murine epithelial cells (LA-4); treatment of infected, human bronchial 16-HBE cells with 38 
25(OH)D liposomes however resulted in a significant reduction in bacterial survival. Together 39 
with the importance of selecting an application-appropriate in vitro model, the current study 40 
illustrates the feasibility and practicality of employing liposomes as a means to achieve 41 
25(OH)D lung deposition. 25(OH)D-loaded liposomes further demonstrated promising effects 42 
regarding prevention of Pseudomonas infection in human bronchial epithelial cells. 43 
 44 
Keywords: Liposome aerosol, calcifediol, cystic fibrosis, poorly soluble drugs, 45 
Pseudomonas aeruginosa, pulmonary drug delivery 46 
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Introduction 48 
Cystic fibrosis (CF) is an autosomal recessive genetic disease, characterised by persistent and 49 
recurring infection of the lungs [1, 2]. A chronic inflammation in response to the presence of 50 
pathogens also develops in CF patients, which is mainly characterised by the accumulation of 51 
neutrophils [3-6]. Continuing infection and inflammation lead to a progressive destruction of 52 
the lung tissue, with subsequent respiratory failure being the ultimate outcome [7]. The 53 
causative agents of infection in CF are limited to a relatively narrow spectrum of pathogens, 54 
with Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa being the 55 
most prevalent organisms [1, 6, 8]. Despite progress in the development of antibiotic therapy, 56 
pulmonary infections still dictate the fate of most CF patients. Effective antimicrobial 57 
treatment of CF-associated infection is presently limited by several factors, including 58 
development of bacterial resistance against the antibiotics commonly in use (exacerbated by 59 
the common need for regular or prophylactic antibiotic therapy), as well as a lack of novel 60 
anti-infectives currently in the pharmaceutical pipeline [9-11].  61 
 62 
The role of vitamin D3 in the regulation of immune and host defence reactions is well 63 
described, as is its influence on the release of inflammatory mediators from neutrophils and 64 
macrophages [12-15]. In recent years a connection between vitamin D3 and pulmonary 65 
diseases such as asthma and chronic obstructive lung disease has been suggested, and a clear 66 
link between vitamin D3 deficiency and respiratory tract infections in patients has been 67 
postulated [16, 17]. Interestingly, low serum levels of vitamin D3 have been found 68 
specifically in CF patients, probably as a result of malabsorption [18]. Therefore, it may be 69 
hypothesised that the administration of vitamin D3 or its metabolites directly to the lung of 70 
CF patients could lead to an improved clinical outcome. Unfortunately however, the poor 71 
water solubility of these compounds necessitates dissolution in organic solvents such as 72 
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ethanol, which limits administration in vivo. Therefore, to enable pulmonary delivery of 73 
vitamin D3 and to study its potential effects on CF-relevant infections, aerosolisable 74 
liposomes of the vitamin D3 metabolite calcifediol (25(OH)D) were developed and 75 
characterised in the current work. The potential of 25(OH)D liposomes to act as a local 76 
delivery system to prevent P. aeruginosa infection was then tested in vitro in two different 77 
cell models. 78 
 79 
Materials and Methods 80 
Material 81 
Dipalmitoylphosphatidylcholine (DPPC) was obtained as a kind gift from Lipoid GmbH 82 
(Ludwigshafen, Germany). Calcifediol (25(OH)D, Ph.Eur/USP) was provided by Dishman 83 
Netherlands (Veenendaal, The Netherlands). 1,2 dipalmitoyl-sn-glycero-3-84 
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) ammonium salt (Rh-DPPE) was 85 
purchased from Avanti Polar Lipids (Alabaster AL, USA). Distilled de-ionised water having a 86 
conductivity of less than 18.2 MΩ/cm at 25°C was used throughout the study. All the other 87 
solvents and chemicals used were of at least analytical grade. For cell cultivation, Ham’s F12 88 
medium containing 15% or DMEM-HamF12 (1:1) with foetal bovine serum (FBS) (all from 89 
Life Technologies, Darmstadt, Germany), penicillin and streptomycin (both Life 90 
Technologies, Darmstadt, Germany)  and Ultroser-G (Pall, Fribourg, Switzerland) were used.  91 
 92 
Liposome preparation and characterisation 93 
Liposome formulations were prepared based on a modified version of the lipid film hydration 94 
method [19]. Briefly, DPPC and 25(OH)D or DPPC alone (total weight 75 mg) were 95 
dissolved in 5 ml of ethyl acetate/methanol (4:1 v/v) in a round-bottomed flask. Following 96 
dissolution, 0.1 ml of a 0.5 mg/ml solution of Rh-DPPE was added and mixed. The organic 97 
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solvent mixture was then evaporated under reduced pressure and with a rotation speed of 145 98 
rpm at 70 °C using a rotavapor (Büchi, Essen, Germany). The resulting homogenous thin lipid 99 
film was then re-hydrated by the addition of 5 ml of deionised water, followed by further 100 
rotation at 60 °C for 1 h. The formed liposomal dispersion was sonicated in a sonication bath 101 
(Bandelin Sonorex, Berlin, Germany) for 10 min and then extruded (LiposoFast extruder, 102 
Avestin, Mannheim, Germany) repeatedly through 200 nm pore size membranes (AMD 103 
Manufacturing Inc., Ontario, Canada) to achieve size reduction and uniformity. Liposomes 104 
were then diluted 1:10 with deionised water and stored at 4 °C under nitrogen until further 105 
use. Physical characterisation of diluted liposomal formulations was performed by dynamic 106 
light scattering (size and size distribution) and electrophoretic mobility (zeta potential) at 25 107 
°C using a Zetasizer Nano (Malvern Instruments Ltd, Worcestershire, United Kingdom). 108 
 109 
Determination of liposomal DPPC and 25(OH)D content 110 
The amount of 25(OH)D incorporated within liposomes was determined via HPLC, 111 
performed on a Dionex HPLC system (Thermo Scientific, Bremen, Germany) composed of a 112 
P680 pump, an Elite degassing System, an Asta-medica AG 80 column oven and a UV 113 
detector. A LiChrospher® RP-18 (5 µm, 125 x 4 mm) column (Merck KGaA, Darmstadt, 114 
Germany) was employed. A mobile phase of methanol/acetonitrile (30:70 v/v) was used, with 115 
an injection volume of 100 ul, a flow rate of 2 ml/min and a temperature of 30 °C. For sample 116 
analysis, liposomes were first dissolved in a mixture of 50% ethyl acetate/methanol (4:1) and 117 
50% acetonitrile. The 25(OH)D content of dissolved liposome samples was determined using 118 
UV detection at a wavelength of 265 nm, and calculated in reference to standard solutions of 119 
25(OH)D. The determined amount of 25(OH)D was then used to calculate the encapsulation 120 
efficiency (EE) of liposomes, defined as the measured amount of 25(OH)D as percentage of 121 
the initially added amount [20]. 122 
 123 
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The amount of DPPC present in liposome formulations was assessed according to the Bartlett 124 
assay [21]. Briefly, a calibration curve was constructed from a stock solution of 0.05 mg/ml 125 
potassium phosphate (Sigma-Aldrich, St. Louis, Missouri, USA) diluted as required with 126 
deionised water to produce standards of known concentration. Both liposome samples and 127 
standards were dried completely in a sand bath at 180 °C prior to any analysis. A 450 µl 128 
volume of 70% perchloric acid (AppliChem, Darmstadt, Germany) was then added to both 129 
samples and standards, followed by incubation at 250-260 °C for 30 min. After cooling, 3.5 130 
ml of deionised water, 500 µl of 2.5% w/v ammonium molybdate solution and 500 µl of 10% 131 
w/v ascorbic acid solution (both from VWR BDH Prolabo, Darmstadt, Germany) were added 132 
to vials of sample and standards, to initiate the colorimetric reaction. The final mixtures were 133 
vortexed and incubated in a water bath at 100 °C for 7 min. The reaction was then stopped by 134 
placing the vials in an ice bath. Subsequently, the UV absorbance of standard solutions and 135 
samples was measured at 820 nm (Lambda 35 UV/VIS Spectrophotometer, Perkin Elmer, 136 
Waltham, USA). 137 
 138 
With the determined amounts of DPPC and 25(OH)D a loading efficiency (LE) was 139 
calculated, expressed as the quantified drug/lipid molar concentration ratio as percentage of 140 
the initial drug/lipid molar concentration ratio [22]. 141 
 142 
Aerosolisation of liposomes 143 
Prior to deposition studies, the effect of the nebulisation process on the colloidal stability of 144 
liposomes was assessed. Liposomes were dispersed in water and nebulised using an electronic 145 
vibrating membrane inhaler (eFlow, PARI Medical Holding GmbH Starnberg, Germany). For 146 
stability, nebulised liposome samples were collected and the diluted liposomal aerosol was 147 
measured for size and zeta potential, as mentioned in the previous section.  148 
 149 
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For investigating the aerodynamic properties of nebulised liposomes, a next-generation 150 
impactor (NGI, Copley Scientific, Nottingham, UK) was used. Deposition experiments were 151 
conducted according to the procedure specified in the European Pharmacopoeia [23] and as 152 
detailed further in the supplementary material. The amount of deposited liposomes in each 153 
NGI stage was determined by measuring the fluorescence of Rh-DPPE using a plate reader 154 
(Genios Pro Tecan, Männedorf, Switzerland, excitation wavelength = 560 nm, emission 155 
wavelength = 662 nm). To predict pulmonary deposition in vivo, parameters of Mass Median 156 
Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD) and Fine Particle 157 
Fraction (FPF) were calculated. For determination of the MMAD and GSD, probit analysis 158 
[24] was employed. FPF was defined as the mass of aerosolised material with an aerodynamic 159 
diameter of less than 5 μm. 160 
 161 
Bacteria cultivation 162 
To determine the influence of 25(OH)D on the immune response to infection, heat inactivated 163 
or viable P. aeruginosa PAO1 cultured as described previously [25] were used. The viable 164 
bacterial suspension was diluted 1:10 in phosphate-buffered saline (PBS, without Ca2+ and 165 
Mg2+, pH 7.4, Life Technologies, Darmstadt, Germany) prior to application. For heat 166 
inactivation the undiluted bacterial suspension was incubated for 10 min at 95 °C, and 167 
subsequently stored in aliquots corresponding to 3x107 colony-forming units (CFU) /ml at -20 168 
°C. To determine bacterial concentrations prior to use, serial dilutions were plated on LB-agar 169 
and cultured overnight. 170 
 171 
Cell culture 172 
Cells of the murine epithelial cell line LA-4 were cultured at 37 °C with 5% CO2, and split at 173 
regular intervals. For measuring inflammatory responses, cells were seeded in a 12-well plate 174 
(Greiner Bio-One GmbH, Frickenhausen, Germany; 0.26x104 cells/cm2) and cultured in 175 
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Ham’s F12 medium containing 15% FBS and 1% penicilin-streptomycin. Cells were treated 176 
under submerged conditions. 177 
 178 
The human bronchial epithelial cell line 16-HBE was cultured in DMEM-HamF12 (1:1) with 179 
10% FBS, penicillin (100 U/ml), and streptomycin (0.1 mg/ml) at 37 °C with 5% CO2, and 180 
split at regular intervals. For infection experiments, cells were seeded under standard 181 
conditions on 12-well Transwell® plates (Corning Inc., Acton, MA, USA). After reaching 182 
confluency the medium was removed from the upper compartment, in order to achieve an air 183 
liquid interface setup for subsequent stimulation [26], and the medium of the basolateral 184 
compartment was changed to DMEM-HamF12 (1:1) containing only 2% Ultroser-G. 185 
 186 
25(OH)D pre-treatment and bacterial challenge 187 
In all cases, cells were first pre-treated with 25(OH)D either within liposomes or dissolved in 188 
0.5% ethanol (40 ng of 25(OH)D/well), or appropriate controls (empty liposomes at 376.7 ng 189 
of DPPC/well, or 0.5% ethanol alone) for 24 h. For all experiments, the dose of empty DPPC 190 
liposomes administered was standardised on the amount of lipid calculated to be contained 191 
within a dose of 25(OH)D liposomes. Following pre-treatment, murine LA-4 cells were 192 
stimulated with heat inactivated P. aeruginosa, while 16-HBE cells were infected with 1x103 193 
CFU/well live bacteria, diluted in PBS to a final volume of 100 µl. In the case of LA-4 cells, 194 
following a 6 h incubation period, apical release of the murine IL-8 homologue KC was 195 
determined by enzyme-linked immunosorbent assay (ELISA) as described below. Survival of 196 
bacteria in the apical compartment of 16-HBE cultures was quantified by plating on LG-agar 197 
and CFU counting after overnight incubation. The final CFU in pre-treated samples was 198 
expressed as a percentage of the CFU of infected samples without pre-treatment.  199 
 200 
 201 
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Measurement of cytokines 202 
The concentration of KC in cell culture supernatants was determined by ELISA according to 203 
the kit manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). A TECAN Ultra 204 
384 ELISA reader together with Magellan software (Mainz, Germany) was employed for 205 
quantification. 206 
 207 
Statistical analysis 208 
Data are expressed as mean ± standard error of the mean (SEM). The data was analysed using 209 
SigmaPlot Version 11 (Systat Software Inc., San Jose, CA, USA). Comparisons between 210 
groups were performed using Student´s t test (two-sided), or ANOVA with post-hoc 211 
Bonferroni adjustment for experiments with more than two subgroups. Results were 212 
considered statistically significant at p values <0.05. 213 
 214 
Results 215 
Liposome preparation and characterisation 216 
Liposomal formulations consisting of DPPC and 25(OH)D (PD), or DPPC alone as a control 217 
(P) were prepared, and characterised firstly in terms of colloidal properties. Both formulations 218 
had a mean initial size below 200 nm, a polydispersity index (PDI) below 0.1 and a negative 219 
zeta potential around -8 mV. With respect to chemical properties, an encapsulation efficiency 220 
and loading capacity of approximately 23% and 46% respectively was found for the PD 221 
preparation (Table 1). PD liposomes were also seen to exhibit constant colloidal properties 222 
upon storage for a period of at least 25 days (Figure S1a, S1b), and to retain the entire 223 
incorporated amount of 25(OH)D for a period of at least 3 days post-preparation (Figure S1c). 224 
Liposomal 25(OH)D was further determined to be active, confirming that the process of 225 
liposome preparation itself (involving for example the use of organic solvents and elevated 226 
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temperatures) had no adverse effect on 25(OH)D stability (Figure S2). The preparation 227 
process and employed conditions were moreover proven to be well translatable, as 228 
demonstrated by the ability to form liposomes utilising vitamin D3 itself as cargo (Table S1, 229 
Figure S3).  230 
 231 
Aerosol deposition studies 232 
The PD formulation was physically stable upon nebulisation, with no appreciable difference 233 
in liposome size and zeta potential noted before and after the nebulisation procedure (Figure 234 
1). The deposition profile of PD liposomes is shown in Figure 2. A high percentage of 235 
liposomes was recovered in the initial stages of the NGI, in particular between stages 1 and 4, 236 
showing that the aerodynamic diameter of the majority of PD liposomes is higher than 3.18 237 
µm. An MMAD of approximately 5.9 µm, a GSD of approximately 2.1 and an FPF of 41% 238 
were calculated from obtained NGI data. 239 
 240 
Effect on P. aeruginosa infection 241 
The efficacy of the 25(OH)D-loaded liposome formulation PD against P. aeruginosa 242 
infection was first investigated in cells of the murine epithelial cell line LA-4. Surprisingly, 243 
treatment of cells with 25(OH)D liposomes or even with 25(OH)D in ethanolic solution prior 244 
to bacterial stimulation was not seen to lead to a significant reduction in KC release, relative 245 
to cells which were treated with PBS alone (Figure 3). This lack of significant 25(OH)D 246 
effect was also noted in a pilot study in an in vivo mouse model (Figure S4). 247 
 248 
In contrast, PD liposomes were seen to impact on P. aeruginosa infection in human 16-HBE 249 
cells. Loaded liposomes were compared with 25(OH)D dissolved in ethanol, and while both 250 
formulations demonstrated an anti-microbial effect, a significantly lower bacterial survival 251 
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was found following treatment with the PD liposomes compared to 25(OH)D dissolved in 252 
ethanol (Figure 4). 253 
Discussion 254 
In order to develop a novel anti-inflammatory and anti-infective approach for treatment of CF 255 
lung disease, and to overcome difficulties in administration resulting from the poor aqueous 256 
solubility of 25(OH)D, a stable liposomal formulation was successfully designed and 257 
prepared. While an anti-inflammatory and anti-infective activity of this formulation was not 258 
notable in murine models, studies in human-derived cell cultures showed a protective effect of 259 
liposomal 25(OH)D against P. aeruginosa infection. 260 
 261 
Although the employed liposomal formulation was also seen to be compatible with vitamin 262 
D3 itself (see supplementary material), the vitamin D3 metabolite 25(OH)D was rather 263 
selected as the specific liposomal cargo in the current work, due to the absence of the vitamin 264 
D3-activating enzyme 25-hydroxylase in pulmonary epithelial and immune cells [17]. In 265 
addition to increasing its effective solubility, incorporation of 25(OH)D into liposomes was 266 
hypothesised to counteract the well-known instability of this compound. However, the effect 267 
of liposome preparation conditions on the stability and continued activity of 25(OH)D was 268 
unknown. The compound was therefore first dissolved in ethanol and subjected to different 269 
stresses (heat, organic solvent and air exposure) as encountered in the liposome preparation 270 
procedure. Encouragingly, only air exposure combined with lipopolysaccharide (LPS) 271 
administration was found to decrease 25(OH)D activity (supplementary material Figure S2). 272 
Therefore, in order to minimize air exposure and maintain 25(OH)D stability, liposomes were 273 
prepared under nitrogen. 274 
 275 
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Due to its lipophilicity, 25(OH)D is expected to be more concentrated within vesicular lipid 276 
bilayers rather than in the bilayer spaces or aqueous core of liposomes [27]. The steroid-like 277 
structure of 25(OH)D in combination with this intra-bilayer location is also known to have the 278 
advantage of condensing and stabilising liposomal bilayers without the need for other 279 
membrane-stabilising components, such as cholesterol [27]. Accordingly, incorporation of 280 
25(OH)D into liposomes in the current work appeared to reduce liposome size and PDI (Table 281 
1). The gained stability data, which showed a high and constant level of 25(OH)D entrapment 282 
and consistent colloidal characteristics over time (Figure S1), further confirmed the stabilising 283 
effect of 25(OH)D on liposomes. 284 
 285 
As a further step in the formulation characterisation process, information about the lung 286 
deposition of PD liposomes was gained by nebulisation of liposomes into an NGI. A lack of 287 
appreciable difference in colloidal parameters pre- and post-nebulisation (Figure 1) indicated 288 
that the vibration of the nebuliser membrane did not destroy or considerably alter the 289 
liposomal structure, confirming the feasibility of deposition studies themselves. NGI 290 
experiments were considered as essential to investigate the aerodynamic deposition of the 291 
prepared liposomes, and to assess their potential for local airway administration (Figure 2). 292 
The calculated MMAD is an encouraging result, as it has been shown that particles with a size 293 
of up to 5 µm can effectively reach the bronchiolar region of the respiratory tract, where 294 
infection and inflammatory responses are mostly localised in CF patients [28]. FPF was 295 
calculated as a measure of the portion of the inhaled mass of liposomes capable of reaching 296 
the lower airways (alveolar region). According to NGI experiments, only 41% of the 297 
liposomal dispersion is expected to reach the alveolar region, while the remaining deposited 298 
fraction will be localised in the bronchiolar region where the action of 25(OH)D is 299 
specifically required. 300 
 301 
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Somewhat surprisingly, neither application of PD liposomes nor of an ethanolic solution of 302 
25(OH)D to infected, mouse-derived LA-4 cells was noted to have an anti-inflammatory 303 
effect (Figure 3). This observation was also supported by an in vivo pilot study in mice 304 
(Figure S4). The lack of effect of 25(OH)D either as ethanolic solution or in liposomes in 305 
such mouse-based models points to significant species differences, with the consequence that 306 
murine models may not be suitable for investigation of 25(OH)D-mediated 307 
immunomodulation in the context of a potential clinical application to patients. This view is 308 
also supported by recent reports on inter-species difference in the immunomodulatory effects 309 
of vitamin D3 and its metabolites between mice and primates [29-31]. The predictive value of 310 
murine models, either in vitro or in vivo, for the translation of this therapeutic approach into 311 
the clinic, may therefore be limited.  312 
 313 
However, when applied to Pseudomonas-infected human 16-HBE cells, PD liposomes 314 
showed a significantly higher bacterial killing compared with both the empty liposome 315 
formulation (P), and 25(OH)D dissolved in ethanol (Figure 4). In this setting therefore, 316 
incorporation of 25(OH)D into liposomes appears to be more effective than 25(OH)D in 317 
solution. 318 
 319 
Conclusion 320 
A liposomal formulation of 25(OH)D with favourable and robust physico-chemical properties 321 
for local delivery to the lung could be successfully prepared. A beneficial effect of 25(OH)D 322 
with respect to P. aeruginosa infection was clearly observed in a human cell line. In this case, 323 
a significant improvement in antibacterial action was observed as a result of incorporation of 324 
25(OH)D into liposomes as compared with administration in ethanolic solution. 25(OH)D-325 
loaded liposomes therefore appear as a promising anti-infective therapy for CF-related lung 326 
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infection. As all materials required for preparing the formulations used in this study may be 327 
regarded as safe for pulmonary administration in humans, this concept should soon be further 328 
evaluated in clinical studies.    329 
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Figures and Tables 410 
Table 1. Physico-chemical characteristics of 25(OH)D:DPPC liposomes (PD) and DPPC liposomes 411 
(P). Size, polydispersity index (PDI) and surface charge (zeta potential) of PD and P are shown. The 412 
encapsulation efficiency (EE) and the loading capacity (LC) of PD are also given. All data represent 413 
mean ± SEM (n=3) , *** = p<0.001. 414 
 Molar ratio 
25(OH)D:DPPC 
Size (nm) PDI Zeta potential 
(mV) 
EE (%) LC (%) 
PD 1.6:2 151.2±3.3 0.067±0.005 -7.6±1.1(***) 23.4±7.9 46.3±4.6 
P 0:1 180.3 ±1.7 0.121±0.006 -25.6±0.1 -- -- 
  415 
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 416 
 417 
 418 
Figure 1. Physical stability of 25(OH)D-loaded liposomes (PD) subjected to nebulisation. 419 
Physical characteristics of PD before and after the nebulisation process are shown. (a) size 420 
and polydispersity index (PDI); (b) zeta potential. Data represent mean ± SEM (n=3). 421 
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 423 
Figure 2. NGI aerosol stage deposition profiles of 25(OH)D-loaded liposomes (PD). Drug 424 
deposition from the induction port to stage 8 (micro-orifice collector, MOC) of the NGI 425 
specifically is shown. Data represent mean ± SEM (n = 3). 426 
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 429 
Figure 3. Release of KC from mouse-derived LA-4 cells. Cells were treated with 25(OH)D 430 
dissolved in ethanol (25(OH)D), 25(OH)D-loaded liposomes (PD), empty liposomes (P), 431 
ethanol, or PBS for 24 h. Cells were then stimulated with heat inactivated P. aeruginosa 432 
PAO1 for 6 h. Fold increase in KC release was calculated by diving the KC levels after 433 
bacterial stimulation by the respective baseline level before bacterial stimulation. Data 434 
represent mean ± SEM (n=6). 435 
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 436 
Figure 4. Bacterial survival in response to treatment of human-derived 16-HBE cells. Cells 437 
were pre-incubated with 25(OH)D either dissolved in 0.5% ethanol (25(OH)D) or within 438 
liposomes (PD), or with drug free liposomes (P) or ethanol alone (Ethanol) as controls. Cells 439 
were then stimulated with P. aeruginosa. Percentage of bacterial survival was calculated as 440 
the number of living bacteria following treatment relative to the amount of living bacteria on 441 
cells without treatment. Circles represent individual survival measurements, while lines 442 
represent the mean within a treatment group. Data represent mean ± SEM, n = 5. * = p<0.05, 443 
*** = p<0.001. 444 
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